FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153992827> ?p ?o ?g. }

• W2153992827 abstract "To obtain information on cardiovascular morbidity, hypertension control, anemia and mineral metabolism based on the analysis of the baseline characteristics of a large cohort of Spanish patients enrolled in an ongoing prospective, observational, multicenter study of patients with stages 3 and 4 chronic kidney diseases (CKD). Multicenter study from Spanish government hospital-based Nephrology outpatient clinics involving 1129 patients with CKD stages 3 (n = 434) and 4 (n = 695) defined by GFR calculated by the MDRD formula. Additional analysis was performed with GFR calculated using the CKD-EPI and Cockcroft-Gault formula. In the cohort as a whole, median age 70.9 years, morbidity from all cardiovascular disease (CVD) was very high (39.1%). In CKD stage 4, CVD prevalence was higher than in stage 3 (42.2 vs 35.6% p < 0.024). Subdividing stage 3 in 3a and 3b and after adjusting for age, CVD increased with declining GFR with the hierarchy (stage 3a < stage 3b < stage 4) when calculated by CKD-EPI (31.8, 35.4, 42.1%, p 0.039) and Cockcroft-Gault formula (30.9, 35.6, 43.4%, p 0.010) and MDRD formula (32.5, 36.2, 42.2%,) but with the latter, it did not reach statistical significance (p 0.882). Hypertension was almost universal among those with stages 3 and 4 CKD (91.2% and 94.1%, respectively) despite the use of more than 3 anti-hypertensive agents including widespread use of RAS blockers. Proteinuria (> 300 mg/day) was present in more than 60% of patients and there was no significant differences between stages 3 and 4 CKD (1.2 ± 1.8 and 1.3 ± 1.8 g/day, respectively). A majority of the patients had hemoglobin levels greater than 11 g/dL (91.1 and 85.5% in stages 3 and 4 CKD respectively p < 0.001) while the use of erythropoiesis-stimulating agents (ESA) was limited to 16 and 34.1% in stages 3 and 4 CKD respectively. Intact parathyroid hormone (i-PTH) was elevated in stage 3 and stage 4 CKD patients (121 ± 99 and 166 ± 125 pg/mL p 0.001) despite good control of calcium-phosphorus levels. This study provides an overview of key clinical parameters in patients with CKD Stages 3 and 4 where delivery or care was largely by nephrologists working in a network of hospital-based clinics of the Spanish National Healthcare System." @default.
• W2153992827 created "2016-06-24" @default.
• W2153992827 creator A5004411532 @default.
• W2153992827 creator A5006630740 @default.
• W2153992827 creator A5023749698 @default.
• W2153992827 creator A5038781045 @default.
• W2153992827 creator A5039134021 @default.
• W2153992827 creator A5043681498 @default.
• W2153992827 creator A5046692355 @default.
• W2153992827 creator A5055273250 @default.
• W2153992827 creator A5064592202 @default.
• W2153992827 creator A5075935909 @default.
• W2153992827 creator A5081216667 @default.
• W2153992827 date "2011-10-05" @default.
• W2153992827 modified "2023-10-06" @default.
• W2153992827 title "Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study" @default.
• W2153992827 cites W1854187713 @default.
• W2153992827 cites W1977808727 @default.
• W2153992827 cites W1998943227 @default.
• W2153992827 cites W2013453412 @default.
• W2153992827 cites W2014648882 @default.
• W2153992827 cites W2028302756 @default.
• W2153992827 cites W2045516356 @default.
• W2153992827 cites W2048615123 @default.
• W2153992827 cites W2051853203 @default.
• W2153992827 cites W2052472016 @default.
• W2153992827 cites W2052844027 @default.
• W2153992827 cites W2053664655 @default.
• W2153992827 cites W2061634360 @default.
• W2153992827 cites W2091886687 @default.
• W2153992827 cites W2103547100 @default.
• W2153992827 cites W2114720788 @default.
• W2153992827 cites W2119886012 @default.
• W2153992827 cites W2120969802 @default.
• W2153992827 cites W2123196786 @default.
• W2153992827 cites W2126558222 @default.
• W2153992827 cites W2142343307 @default.
• W2153992827 cites W2145632027 @default.
• W2153992827 cites W2155965977 @default.
• W2153992827 cites W2160134719 @default.
• W2153992827 cites W2166159490 @default.
• W2153992827 cites W2488868277 @default.
• W2153992827 cites W4211062471 @default.
• W2153992827 doi "https://doi.org/10.1186/1471-2369-12-53" @default.
• W2153992827 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3203029" @default.
• W2153992827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21970625" @default.
• W2153992827 hasPublicationYear "2011" @default.
• W2153992827 type Work @default.
• W2153992827 sameAs 2153992827 @default.
• W2153992827 citedByCount "74" @default.
• W2153992827 countsByYear W21539928272012 @default.
• W2153992827 countsByYear W21539928272013 @default.
• W2153992827 countsByYear W21539928272014 @default.
• W2153992827 countsByYear W21539928272015 @default.
• W2153992827 countsByYear W21539928272016 @default.
• W2153992827 countsByYear W21539928272017 @default.
• W2153992827 countsByYear W21539928272018 @default.
• W2153992827 countsByYear W21539928272019 @default.
• W2153992827 countsByYear W21539928272020 @default.
• W2153992827 countsByYear W21539928272021 @default.
• W2153992827 countsByYear W21539928272022 @default.
• W2153992827 countsByYear W21539928272023 @default.
• W2153992827 crossrefType "journal-article" @default.
• W2153992827 hasAuthorship W2153992827A5004411532 @default.
• W2153992827 hasAuthorship W2153992827A5006630740 @default.
• W2153992827 hasAuthorship W2153992827A5023749698 @default.
• W2153992827 hasAuthorship W2153992827A5038781045 @default.
• W2153992827 hasAuthorship W2153992827A5039134021 @default.
• W2153992827 hasAuthorship W2153992827A5043681498 @default.
• W2153992827 hasAuthorship W2153992827A5046692355 @default.
• W2153992827 hasAuthorship W2153992827A5055273250 @default.
• W2153992827 hasAuthorship W2153992827A5064592202 @default.
• W2153992827 hasAuthorship W2153992827A5075935909 @default.
• W2153992827 hasAuthorship W2153992827A5081216667 @default.
• W2153992827 hasBestOaLocation W21539928271 @default.
• W2153992827 hasConcept C126322002 @default.
• W2153992827 hasConcept C146357865 @default.
• W2153992827 hasConcept C151730666 @default.
• W2153992827 hasConcept C159641895 @default.
• W2153992827 hasConcept C201903717 @default.
• W2153992827 hasConcept C23131810 @default.
• W2153992827 hasConcept C2778653478 @default.
• W2153992827 hasConcept C2779561371 @default.
• W2153992827 hasConcept C2780091579 @default.
• W2153992827 hasConcept C54847362 @default.
• W2153992827 hasConcept C71924100 @default.
• W2153992827 hasConcept C72563966 @default.
• W2153992827 hasConcept C86803240 @default.
• W2153992827 hasConceptScore W2153992827C126322002 @default.
• W2153992827 hasConceptScore W2153992827C146357865 @default.
• W2153992827 hasConceptScore W2153992827C151730666 @default.
• W2153992827 hasConceptScore W2153992827C159641895 @default.
• W2153992827 hasConceptScore W2153992827C201903717 @default.
• W2153992827 hasConceptScore W2153992827C23131810 @default.
• W2153992827 hasConceptScore W2153992827C2778653478 @default.
• W2153992827 hasConceptScore W2153992827C2779561371 @default.
• W2153992827 hasConceptScore W2153992827C2780091579 @default.
• W2153992827 hasConceptScore W2153992827C54847362 @default.
• W2153992827 hasConceptScore W2153992827C71924100 @default.
• W2153992827 hasConceptScore W2153992827C72563966 @default.

• next